A case of methotrexate resistant gestational trophoblastic neoplasia

Sanjay Singh, Akhileshwar Singh, Shakti Vardhan


Gestational trophoblastic neoplasia (GTN) is a subset of gestational trophoblastic disease (GTD) which has a propensity to invade locally and metastasize. Patients with low risk GTN generally respond well to single agent chemotherapy (methotrexate (MTX) or actinomycin-D (ACT-D). However, high risk cases may develop resistance or may not respond to this first-line chemotherapy and are unlikely to be cured with single-agent therapy. Therefore, combination chemotherapy is used for treatment of these cases. Here we present a 25 years old P2 L2 A1 lady, who was initially treated at a peripheral hospital with multiple doses of Injection methotrexate with a working diagnosis of persistent trophoblastic disease. She didn’t respond to this treatment and reported to our centre for further management. On evaluation she was found to be a case of high risk GTN (invasive mole) (I:8) for which she was put on combination chemotherapy in the form of Etoposide-Methotrexate-Actinomycin-Cyclophosphamide-Oncovin (EMA-CO) regime. She responded to this treatment and is presently asymptomatic and is under regular follow up.


Abnormal uterine bleeding, b-hCG, EMA-CO, Gestational trophoblastic neoplasia, Invasive mole

Full Text:



Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654-62.

Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.

Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;1:CD008891

Ballal PK, Kushtagi PS, Nikil PR. Variation in Prevalence of Gestational Trophoblastic Disease in India. Indian J Gynecol Oncol.2016;14 (3):1-5.

Goldstein DP, Berkowitz RS: Current management of Gestational trophoblastic neoplasia. Hematol Oncol Clin North Am.2012;26(1):111.

Kang WD, Choi HS, Kim SM: Prediction of persistent gestational trophoblastic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. Gynecol Oncol 2012;124(2):250.

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Lancet Oncol. 2003; 4(11):670-8.

FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105(1):3-4.

Sebire NJ, Lindsay I, Fisher RA: Over diagnosis of complete and partial hydatidiform mole in tubal ectopic pregnancies. Int J Gynecol Pathol. 2005;24(3):260.

Horowitz NS, Goldstein DP, Berkowitz RS: Management of gestational trophoblastic neoplasia. Semin Oncol.2009;36(2):181.

Lurain JR. Gestational trophoblastic disease I; epidemiology, pathology, clinical presentation, and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol.2010;203(6):531.

Hanna RK, Soper JT. The role of surgery and radiation therapy in the management of gestational trophoblastic disease. Oncol.2010;15(6):593.

van Trommel NE, Massuger LF, Verheijen RH, Sweep FC, Thomas CM. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecologic Oncol. 2005;99(1):6-13.

Garrett LA, Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. Obstet Gynecol Surv. 2008;63(11):704-5.